MedTrace Logo

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

NCT03883113 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2021-03-18

Study results available
· View outcomes & findings →

Summary

A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult volunteers.

Conditions

Interventions

BIOLOGICAL

MVA-NP+M1

Trial Vaccine

BIOLOGICAL

Saline

Sodium Chloride Placebo

BIOLOGICAL

H3N2 (A/Belgium/2417/2015)

Challenge Agent

Sponsors & Collaborators

  • Barinthus Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Robin Rogiers, MD · SGS S.A.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-03
Primary Completion
2019-12-16
Completion
2020-04-17
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03883113 on ClinicalTrials.gov